Discover
THRD
Third Harmonic Bio, Inc.
5.38
undefined x undefined
undefined x undefined
bid
ask
-
0.00
0.09%
04:00 PM
| Ytd | ||
| 1y |
5.34
day range
5.43
52 week range
| Open | 5.41 | Prev Close | 5.38 | Low | 5.34 | High | 5.43 | Mkt Cap | N/A |
| Vol | 1.42M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -7.01 |
| Beta | 2.86 | Short Ratio | 10.80 | Inst. Own | 92.38% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 19.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-07 | 2024-09 | -0.31 | -0.33 | -0.02 | -6.45% |
| 2024-08-08 | 2024-06 | -0.29 | N/A | N/A | N/A |
| 2024-08-08 | 2024-06 | -0.29 | -0.26 | 0.03 | 10.34% |
| 2024-05-15 | 2024-03 | -0.33 | -0.2 | 0.13 | 39.39% |
| 2024-05-15 | 2024-03 | -0.33 | N/A | N/A | N/A |
| 2024-03-26 | 2023-12 | -0.33 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-08-09 | Morgan Stanley | Upgrade | Equal-Weight | Overweight |
| 2024-06-18 | Stifel | Upgrade | Buy | |
| 2024-06-07 | Raymond James | Upgrade | Outperform | |
| 2023-08-11 | Morgan Stanley | Upgrade | Equal-Weight | Equal-Weight |
| 2022-12-16 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| 2022-12-16 | Jefferies | Downgrade | Buy | Hold |
Profile
Third Harmonic Bio, Inc., a biopharmaceutical company, focuses on the development of the medicine for the treatment of dermal, respiratory, and gastrointestinal inflammatory diseases. The company develops oral small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is also developing THB335, an oral small molecule KIT inhibitor for the treatment of mast cell-mediated skin, respiratory, and gastrointestinal conditions. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was incorporated in 2019 and is headquartered in San Francisco, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-28 | BVF PARTNERS L P | Beneficial Owner of more than 10% of a Class of Security | 176.69K | Sale |
| 2024-11-07 | CONNER EDWARD R | Officer | 0.00 | Conversion of Exercise of derivative security |
| 2024-06-06 | DITTMAN JENNIFER | Officer | 0.00 | Conversion of Exercise of derivative security |
| 2024-05-08 | HOLLES NATALIE C | Chief Executive Officer | 1.22M | Conversion of Exercise of derivative security |
| 2024-09-18 | PERSON JULIE | Officer | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Atlas Venture Life Science Advisors, LLC | 10.91M | 117.80M | 24.21% |
| 2024-09-29 | Orbimed Advisors LLC. | 5.78M | 62.41M | 12.83% |
| 2024-09-29 | BVF Inc. | 4.37M | 47.15M | 9.69% |
| 2024-09-29 | EcoR1 Capital, LLC | 3.18M | 34.37M | 7.06% |
| 2024-09-29 | General Atlantic, L.P. | 2.96M | 31.95M | 6.57% |
| 2024-09-29 | T. Rowe Price Investment Management, Inc. | 2.83M | 30.57M | 6.28% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Price (T.Rowe) Small-Cap Value Fund | 846.79K | 9.15M | 1.88% |
| 2024-09-29 | Price (T.Rowe) Small Cap Stock Fund | 564.62K | 6.10M | 1.25% |
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 517.12K | 5.58M | 1.15% |
| 2024-10-30 | iShares Russell 2000 ETF | 514.59K | 5.56M | 1.14% |
| 2024-09-29 | Price (T.Rowe) U.S. Small-Cap Value Equity Trust | 443.05K | 4.78M | 0.98% |
| 2024-10-30 | Fidelity Advisor Biotechnology Fund | 343.40K | 3.71M | 0.76% |
Dividend
| Dividend | Date |
|---|---|
| 0.12 | 2014-08-06 |
| 0.12 | 2014-05-06 |
| 0.12 | 2014-02-05 |
| 0.1 | 2013-11-06 |
| 0.1 | 2013-08-06 |
| 0.05 | 2013-05-06 |
Split
| Split | Date |
|---|---|
| 1.05 : 1 | 2011-02-15 |